SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Morepen Laboratories reports 29% fall in Q4 consolidated net profit

13 May 2025 Evaluate

Morepen Laboratories has reported results for fourth quarter (Q4) and year ended March 31, 2025.

The company has reported 70.20% fall in its net profit at Rs 11.91 crore for the quarter under review as compared to Rs 39.96 crore for the same quarter in the previous year. The total income of the company decreased by 2.90% at Rs 385.08 crore for Q4FY25 as compared Rs 396.59 crore for the corresponding quarter previous year.

On consolidated basis, the company has reported 29.33% fall in its net profit at Rs 20.31 crore for fourth quarter ended March 31, 2025 as compared to Rs 28.74 crore for the same quarter in the previous year. However, total income of the company increased by 10.10% at Rs 470.46 crore for Q4FY25 as compared Rs 427.32 crore for the corresponding quarter previous year.

For the year ended March 31, 2025, the company has reported 8.44% fall in its net profit at Rs 101.58 crore as compared to Rs 110.94 crore for the previous year. However, total income of the company increased marginally by 1.30% at Rs 1570.25 crore for year under review as compared to Rs 1550.16 crore for year ended March 31, 2024.

For the year ended March 31, 2025, on the consolidated basis, the company has reported 22.15% rise in its net profit at Rs 118.02 crore as compared to Rs 96.62 crore for the previous year. The total income of the company increased by 7.37% at Rs 1829.94 crore for year under review as compared to Rs 1704.40 crore for year ended March 31, 2024.

Morepen Laboratories Share Price

41.27 1.15 (2.87%)
15-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1696.65
Dr. Reddys Lab 1218.30
Cipla 1226.65
Zydus Lifesciences 936.00
Lupin 2339.20
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×